COMPANY PROFILE

LinXis

Explore full profile

Specialized in the development of targeted drugs to treat cancer and chronic diseases

Amsterdam, NetherlandsFounded 2011Biotech & Life Sciences

Valuation $50–100M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About LinXis

LinXis B.V. is a clinical-stage biotechnology company that is developing first-in-class therapeutics and diagnostics for fibrosis. The company is pioneering the use of Fibrobodies® and Fibrobody®-Drug Conjugates to diagnose and combat liver fibrosis and other fibrotic diseases. This targeted drug delivery approach is similar to methods successfully applied in cancer treatment, using Antibody-Drug Conjugates (ADCs).

The company is engaged in a public-private partnership with the Amsterdam University Medical Center called the FIBROTARGET project, which is funded by the Dutch Lung Foundation. This project aims to further develop their technology.

LinXis B.V. was founded in 2011 and is based in Amsterdam, the Netherlands. While some sources indicate a focus on oncology in the past, the company's current focus is clearly on fibrotic diseases.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2011
Headquarters: Amsterdam, Netherlands
Employees: 21
Open positions: None listed
Dealroom signal: 56.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Horizon Europe, DT and LS, science-based
Technology: Nanotech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Aug 2023	$17M	$66M	Undisclosed	—
GRANT✓Other financing	Oct 2018	$550K	—	Undisclosed	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

LinXis website traffic

Latest recorded traffic for LinXis is 510 monthly website visits, up 131.8% over the last three months. LinXis's team grew 0% over the past year.

Latest monthly visits510 3-month web change+131.8% 1-year team growth0%

Monthly website visitsJul 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
COCrossfire OncologyTargeting cancer at its root with kinase-focused radiopharmaceutical innovation	Oss, Netherlands	Operational	14	$605K	—
ASASYLIACompanion Diagnostics For Immunotherapy \| Asylia Diagnostics	Beerse, Belgium	Operational
NANanoligentThe research and development to clinical phases of innovative cancer treatments based on protein nanoparticles	Cerdanyola del Vallès, Spain	Operational
STSeekyo TherapeuticsA privately-owned biotech company developing a Smart Chemotherapy, selective to tumours, safe for patients	Saint-Maur-des-Fossés, France	Operational
TPTagworks PharmaceuticalsThe development of therapeutics that can be released and activated selectively	Nijmegen, Netherlands	Operational
BIBioXplorDeveloping a computational network pharmacology platform to match optimal drug combinations to the right patients	Dublin, Ireland	Operational
SOSDS OpticFirst ever European based cutting-edge medical DeepTech connecting molecular biology with novel photonics technologies, chemistry & biomedical engineering	Lublin, Poland	Operational
DMDamae MedicalMedical device capable of seeing biological tissues in depth, at a cellular level and in vivo	Paris, France	Operational